1 / 12

Observations on Marketed Alpha-1-Proteinase Inhibitor Products Ewa Marszal, PhD FDA/CBER

Observations on Marketed Alpha-1-Proteinase Inhibitor Products Ewa Marszal, PhD FDA/CBER BPAC, November 2005. Presentation Contents Differences between a 1 -PI products Consistency of manufacturing. Differences between a 1 -PI products Contaminating plasma proteins

arnon
Télécharger la présentation

Observations on Marketed Alpha-1-Proteinase Inhibitor Products Ewa Marszal, PhD FDA/CBER

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Observations on Marketed Alpha-1-Proteinase Inhibitor Products Ewa Marszal, PhD FDA/CBER BPAC, November 2005

  2. Presentation Contents Differences between a1-PI products Consistency of manufacturing

  3. Differences between a1-PI products Contaminating plasma proteins Inactive a1-PI (e.g., polymer/latent form) Modifications of the primary structure

  4. Protein impurities (SDS-PAGE, reducing) Prolastin Aralast Zemaira albumin → a1-PI → Specific activity: ≥ 0.35 ≥ 0.55 ≥ 0.7 mg functional a1-PI/mg total protein

  5. Presence of high molecular weight species (SE-HPLC, absorbance@215 nm) M% 95.4 89.8 88.1 (a1-PI + albumin) Zemaira Aralast Prolastin M

  6. Isoelectric focusing (IEF) cathode (-) anode (+) higher pH lower pH zero net charge pH gradient

  7. Heterogeneity of a1-PI in plasma by IEF (charge heterogeneity) 3 polysaccharide chains (sialic acid) N-terminal pentapeptide EDPNG Polymorphism, e.g., E342K

  8. Dominant a1-PI isoforms in plasma (charge heterogeneity) M6 M4 M2 EDPNG N N N EDPNG N N N EDPNG N N N

  9. Heterogeneity of a1-PI products by IEF Plasma Aralast Zemaira Prolastin Plasma Aralast Zemaira Prolastin desialylated M6 → M4 → M2 →

  10. Consistency of manufacturing by IEF Analysis of patients’ plasma from Aralast pivotal clinical trial Analysis of current and historical lots of a1-PI products

  11. Conclusions a1-PI products contain: different levels of contaminating plasma proteins different amounts of inactive a1-PI species different levels of primary structure modifications a1-PI in each product differs somewhat from a1-PI in plasma (IEF, polymer) Manufacturing of each a1-PI product appears to be consistent over time by IEF

  12. Consistency of manufacturing Bayer Baxter Behring Desialylated Non-desialylated

More Related